| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1463-1326.2008.00914.X |
| P698 | PubMed publication ID | 18518892 |
| P50 | author | Juliana Chung-ngor Chan | Q40358533 |
| P2093 | author name string | M J Davies | |
| R Scott | |||
| E Gonzalez | |||
| J M Amatruda | |||
| K D Kaufman | |||
| D Williams-Herman | |||
| P P Stein | |||
| J C Arjona Ferreira | |||
| D Sheng | |||
| P2860 | cites work | Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes | Q46381951 |
| Screening for kidney disease in adults with diabetes | Q46570776 | ||
| Management of glycemia in patients with diabetes mellitus and CKD. | Q46936954 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. | Q51478110 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. | Q51483804 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. | Q51484788 | ||
| Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. | Q51484798 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. | Q51489068 | ||
| Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. | Q51799556 | ||
| Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes | Q58448492 | ||
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses | Q28285795 | ||
| Diabetic nephropathy: diagnosis, prevention, and treatment | Q34379284 | ||
| The biology of incretin hormones | Q34499706 | ||
| Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor | Q34579106 | ||
| Oral antihyperglycemic agents and renal disease: new agents, new concepts | Q36153042 | ||
| Antihypertensive therapy in the presence of proteinuria | Q36690664 | ||
| Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin | Q36773485 | ||
| Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients | Q43603797 | ||
| P433 | issue | 7 | |
| P921 | main subject | patient | Q181600 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 545-555 | |
| P577 | publication date | 2008-06-01 | |
| P1433 | published in | Diabetes, Obesity and Metabolism | Q5270109 |
| P1476 | title | Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency | |
| P478 | volume | 10 |
| Q48223871 | A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment. |
| Q38266290 | A review of gliptins for 2014. |
| Q37965612 | A review of gliptins in 2011. |
| Q38282880 | A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy |
| Q37164446 | A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment |
| Q38067491 | A review of the efficacy and safety of oral antidiabetic drugs |
| Q38902615 | A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease |
| Q38065109 | Achieving glycemic control in patients with type 2 diabetes and renal impairment |
| Q30245199 | Adverse safety events in patients with Chronic Kidney Disease (CKD). |
| Q37141607 | An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease. |
| Q38219489 | Anti-diabetes therapy: safety considerations for patients with impaired kidney function |
| Q51759934 | Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes. |
| Q37690751 | Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus |
| Q38858585 | Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: A systematic review |
| Q37949599 | Choosing a gliptin |
| Q53519441 | Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). |
| Q37346737 | Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin |
| Q40976445 | Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease |
| Q38107347 | Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? |
| Q37428857 | Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential |
| Q38017726 | Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors |
| Q48108721 | Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study. |
| Q35921498 | Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial |
| Q47566180 | Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease |
| Q93523921 | Correspondence (reply): In Reply |
| Q38958933 | Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand |
| Q37860396 | Current and emerging antiglycaemic pharmacological therapies: the renal perspective |
| Q39160771 | Current therapeutic approaches in the management of hyperglycemia in chronic renal disease. |
| Q91638366 | DPP-4 Inhibition and the Path to Clinical Proof |
| Q37638984 | DPP-4 inhibitors in clinical practice. |
| Q34068430 | Diabetes treatment in patients with renal disease: Is the landscape clear enough? |
| Q59220162 | Diabetic nephropathy |
| Q46527122 | Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial |
| Q28294225 | Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials |
| Q38215452 | Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes |
| Q37735838 | Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus |
| Q37992956 | Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? |
| Q35026483 | Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy |
| Q38200670 | Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. |
| Q38018110 | Drug-induced hypoglycaemia in type 2 diabetes |
| Q31171482 | Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: Meta-analysis of randomized controlled trials using unadjusted data |
| Q40844288 | Effects of sulfonylureas on lipids in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials |
| Q35382193 | Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis |
| Q39855313 | Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials |
| Q36782645 | Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency |
| Q86499031 | Evolution of evidence-based medicine to detect evidence mutations |
| Q37772523 | Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone |
| Q35950538 | Glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with renal complications |
| Q33779315 | How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study |
| Q36907473 | Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study |
| Q37858364 | Incretin therapies in the management of elderly patients with type 2 diabetes mellitus |
| Q38012068 | Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment |
| Q37427294 | Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials |
| Q37781456 | Incretin-based Therapy in Chronic Kidney Disease |
| Q37483473 | Incretin-based therapies for type 2 diabetes mellitus |
| Q37316259 | Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. |
| Q57688763 | Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease |
| Q26740630 | Interactions between kidney disease and diabetes: dangerous liaisons |
| Q37281205 | Linagliptin as add-on therapy to insulin for patients with type 2 diabetes |
| Q34891146 | Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. |
| Q37878396 | Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy |
| Q36560252 | Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study |
| Q38004088 | Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis |
| Q30353386 | Management of Diabetic Nephropathy in the Elderly: Special Considerations. |
| Q38378755 | Management of glycemia in diabetic patients with stage IV and V chronic kidney disease |
| Q38497122 | Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin |
| Q38200923 | Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate |
| Q51394933 | Metabolic control and vascular diseases under oral antidiabetic drug versus insulin therapy and/or diet alone during the first year of hemodialysis in type 2 diabetic patients with ESRD. |
| Q98177180 | Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials |
| Q38193694 | Metformin and other antidiabetic agents in renal failure patients |
| Q38778476 | NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis |
| Q37306767 | New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. |
| Q38077451 | Noninsulin glucose-lowering agents for the treatment of patients on dialysis |
| Q31025919 | Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease |
| Q37779779 | Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin |
| Q38086611 | Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease |
| Q38010243 | Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes |
| Q38261573 | Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes |
| Q54603928 | Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. |
| Q39816204 | Pharmacokinetics of Teneligliptin in Subjects With Renal Impairment |
| Q38186638 | Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature |
| Q96135149 | Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus |
| Q46071500 | Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials |
| Q35909303 | Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes |
| Q37952000 | Prevention and management of transplant-associated diabetes |
| Q33898744 | Primary care of the renal transplant patient. |
| Q47140737 | Renal Function During an Open-Label Prospective Observational Trial of Sitagliptin in Patients With Diabetes: A Sub-Analysis of the JAMP Study |
| Q46981976 | Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus. |
| Q28544980 | Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials |
| Q33562235 | Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes |
| Q42209597 | Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis |
| Q41966262 | Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies |
| Q26863262 | Safety of dipeptidyl peptidase 4 inhibitors: a perspective review |
| Q38335751 | Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes |
| Q34078449 | Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis |
| Q35798155 | Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials |
| Q37129133 | Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study |
| Q26739888 | Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy |
| Q37886184 | Sitagliptin: a review |
| Q38177173 | Sitagliptin: a review of its use in patients with type 2 diabetes mellitus |
| Q37703202 | Sitagliptin: a review of its use in the management of type 2 diabetes mellitus |
| Q28075368 | Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment |
| Q92316034 | The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect |
| Q37502682 | The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups |
| Q33583220 | The effects of glucose-lowering therapies on diabetic kidney disease |
| Q33866808 | The evolving place of incretin-based therapies in type 2 diabetes |
| Q38137027 | The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis |
| Q49592715 | The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial |
| Q33698333 | The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease |
| Q51131443 | Time of effect duration and administration interval for sitagliptin in patients with kidney failure. |
| Q28077026 | Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists |
| Q28073342 | Update on the treatment of type 2 diabetes mellitus |
| Q37857686 | Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin |
| Q38036778 | Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease |
Search more.